A panel for women by women highlighted key things to keep in mind when starting a company. Getty Images

Laying the proper foundation of a startup might be one of the most important parts of starting a company — right behind the innovative solution your startup aims to provide.

At a female-founder focused panel at Baker Botts cohosted by The Artemis Fund earlier this month, a group of experts gave their advice from managing contracts and hiring to salary and investment.

The panel was moderated by Grace Rodriguez, CEO and executive director of Impact Hub Houston, and featured an investor, a founder, and a legal representative — Leslie Goldman, general partner and co-founder of The Artemis Fund; Emma Fauss, CEO of Medical Informatics Corp.; and Katie Belleville, associate at Baker Botts L.L.P, respectively.

If you missed the event, here are four pieces of advice from the panelists.

Be aware of an investor's founder red flags

When asked about what she looks for in a potential investment opportunity, Goldman, who's fund invests in female-led startups, looks at a myriad of things, but the big one is the founder herself.

"Ninety percent of it is about the founder," Goldman says on the panel. "The founder is key."

She goes on to say that her founder red flags include lack of transparency, not knowing her numbers, and not having the proper legal paperwork in order.

Representing the legal side, Belleville echoed the importance of getting the proper legal paperwork together from day one.

"It is important to get you organizational documents in order in the beginning to avoid a problem later down the line," Belleville says. "Going to a lawyer to help you set up your company and what documents you need."

She adds that startup founders can expect to pay lawyers by the hour like most legal exchanges, but a lot of legal professionals will offer a preliminary meeting to understand each other for free.

Be smart about who's giving you money

For Fauss, who closed an $11.9 million round in January, and most entrepreneurs, finding investors is a huge challenge and commitment.

"Raising money is probably my least favorite activity. It's a brutal process," Fauss tells the audience. "You are getting married to someone for 20-plus years. And it's easier to get a divorce from your husband than it is to get a divorce from your board members."

She explains how keeping that in mind really led her to be picky about her investors and find ones that were right for her and her company.

When it comes to hiring and salary — get it on paper

Every founder will eventually get to a point when they'll need to hire as their company grows. Fauss says she was fortunate to find her early team members organically — through networking opportunities. When it comes to listing jobs online, she recommends being specific to what expertise you're looking for.

In tandem with hiring, founders must decide how they plan to compensate their employees and whether they offer equity — something Goldman says impresses her.

"If a founder convinced other people to join their team based on a promise of getting a part of the company, it means that they are a charismatic entrepreneur and it means that the people who join them believe strongly and passionately about the company," Goldman says.

Belleville adds that founders should be aware of employment agreements, which she doesn't think is necessary in every situation, and confidentiality agreements, which she highly recommends when it comes to protecting the company's intellectual property.

"If you make it part of the [on boarding] process, then everyone has one and you've got that security at the point when they're leaving," Belleville says.

At one point in the panel, Fauss brings up a salary issue she's passionate about.

"Don't forget to budget in your own salary," Fauss says. "Your sweat equity, your worth does have a cost."

She adds that even if you're not getting paid a full salary when you're starting out, it's important to keep in the budget especially when factoring VC money.

Keep your paperwork in order

This might be a no-brainer, but the panelists all echoed the need for properly organized paperwork, especially when it comes to contracts and letters of intent with clients, for general bookkeeping reasons but also for review of potential investors.

"I'm going to want to see that there's actually a binding contract there," Goldman says, adding that the legality and terms of those types of agreements are crucial for her role as an investor.

Belleville says that one way for founders to keep track is by making a detailed spreadsheet with all that's in the contracts — terms, renewal, and termination details, for example.

The panelists — and even some founders in the audience — recommended digital filing systems like Carta, or its free version called captable.io. DocSend was also recommended for sharing your pitch deck because it offers stats so you can see how much time was spent on each page. At the very least, founders should keep files backed up online in Google Docs or DropBox.

When it comes to issuing contacts, Fauss recommends working with a legal team to streamline that process. Ninety percent of contracts will stay the same between clients, she says, so put together a playbook to know which variables to use and when.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.